This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 2009; 23: 1999–2006.
Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008; 14: 3881–3888.
Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE . Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008; 112: 3348–3354.
Weisberg E, Catley L, Wright RD, Moreno D, Banerji L, Ray A et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 2007; 109: 2112–2120.
White DL, Saunders VA, Quinn SR, Manley PW, Hughes TP . Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs. Blood 2007; 109: 3609–3610.
Engler J, Frede A, Zannettino A, White D, Hughes T . Reduced activity of the OCT-1 protein in primitive CML cells: a likely determinant of stem cell resistance in imatinib treated CML patients. Blood 2008; 112: 80 (abstract 196).
Hatziieremia S, Jordanides NE, Holyoake TL, Mountford JC, Jorgensen HG . Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Exp Hematol 2009; 37: 692–700.
Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926–935.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hiwase, D., White, D., Zrim, S. et al. Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Leukemia 24, 658–660 (2010). https://doi.org/10.1038/leu.2009.242
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2009.242
This article is cited by
-
Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib
Clinical Pharmacology & Therapeutics (2014)
-
ABC Transporters in Multi-Drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors
Pharmaceutical Research (2014)
-
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase
Leukemia (2012)
-
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
Leukemia (2011)
-
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
Leukemia (2010)